Metabolic flux model for an anchorage-dependent MDCK cell line: characteristic growth phases and minimum substrate consumption flux distribution.
Up to now cell-culture based vaccine production processes only reach low productivities. The reasons are: (i) slow cell growth and (ii) low cell concentrations. To address these shortcomings, a quantitative analysis of the process conditions, especially the cell growth and the metabolic capabilities of the host cell line is required. For this purpose a MDCK cell based influenza vaccine production process was investigated. With a segregated growth model four distinct cell growth phases are distinguished in the batch process. In the first phase the cells attach to the surface of the microcarriers and show low metabolic activity. The second phase is characterized by exponential cell growth. In the third phase, preceded by a change in oxygen consumption, contact inhibition leads to a decrease in cell growth. Finally, the last phase before infection shows no further increase in cell numbers. To gain insight into the metabolic activity during these phases, a detailed metabolic model of MDCK cell was developed based on genome information and experimental analysis. The MDCK model was also used to calculate a theoretical flux distribution representing an optimized cell that only consumes a minimum of carbon sources. Comparing this minimum substrate consumption flux distribution to the fluxes estimated from experiments unveiled high overflow metabolism under the applied process conditions.
Wahl
Aljoscha
A
Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstr. 1, 39106 Magdeburg, Germany. awahl@mpi-magdeburg.mpg.de
Sidorenko
Yury
Y
Dauner
Michael
M
Genzel
Yvonne
Y
Reichl
Udo
U
D000818:Animals; D002460:Cell Line; D049109:Cell Proliferation; D003198:Computer Simulation; D004285:Dogs; D007252:Influenza Vaccines / Q000235:genetics* / Q000378:metabolism*; D007668:Kidney / Q000502:physiology*; D008657:Metabolic Clearance Rate; D008954:Models, Biological
D007252:Influenza Vaccines